MeiraGTx Q1 net loss $40.0M; announces $200M Hologen AI collaboration, RMAT for AAV-GAD

MeiraGTx Holdings plc

2025-Q1 EPS reported -$0.51 revenue$1,926,000

Q1 net loss $40.0M ($0.51/share) vs $20.4M ($0.32) YoY; revenue $1.9M; cash $66.5M.
Hologen AI collaboration: $200M upfront to MeiraGTx; joint venture with $230M committed capital.
FDA granted RMAT designation for AAV-GAD Parkinson's; Phase 3 study planned H2 2025.
AAV-AIPL1 data in Lancet: 11/11 children with LCA4 responded; expedited approval discussions underway.
Bota-vec Phase 3 XLRP trial primary endpoint not met; secondary endpoints showed benefit across vision domains.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.